Chesson Labs receives market clearance for Nuvaderm liquid bandage
DURHAM, N.C. Chesson Labs on Wednesday announced receiving 510(k) market clearance from the Food and Drug Administration for its Nuvaderm liquid bandage for use by healthcare professionals or directly to consumers.
The FDA has cleared claims on the product “to cover intact skin and minor cuts, scrapes, burns or irritations of the skin, to help keep them clean and dry and help protect them from infection.” The fast application, drying and coverage characteristics make Nuvaderm suited to meet the needs of individuals treating minor wounds, the company stated. The product also has antimicrobial properties.
“Nuvaderm’s clearance is a major milestone for Chesson Labs, but more importantly it is a product developed to improve wound care for individuals treating themselves as well as medical personnel who need a rapid response product to treat minor wounds,” stated Scott Neuville, Chesson president and CEO.
Study finds probiotics may bolster immune system in children
SAN BRUNO, Calif. A study recently published in the journal Pediatrics has found that probiotics may be able to bolster the immune system in children well enough to ward off cold and flu viruses, Biocodex reported last week.
Patricia Raymond, assistant professor at Eastern Virginia Medical School, advised to consider the use of Florastor to help strengthen the gut.
“Consider the use of Saccharomyces boulardii (S. boulardii), a yeast-based probiotic supplement commonly sold under the brand name Florastor,” she said. “Data has shown that S. boulardii can modify the inflammation and secretion of the gut, neutralize toxins and decrease various pathogens’ ability to attach to the wall of the intestine.”
Florastor is also available as Florastor Kids, Biocodex stated.
WHO: Pregnant women infected with H1N1 virus experience fatal illnesses
GENEVA The World Health Organization on Friday stated that research — conducted in the United States and published July 29 in The Lancet — outlining increased risk of severe or fatal illness in pregnant women when infected with the H1N1 pandemic virus has been observed in several other countries experiencing widespread transmission of the virus.
Women are at particular risk during the second and third trimesters of pregnancy. An increased risk of fetal death or spontaneous abortions in infected women has also been reported. Evidence from previous pandemics further supports the conclusion that pregnant women are at heightened risk, WHO added.
WHO strongly recommends that, in areas where infection with the H1N1 virus is widespread, pregnant women, and the clinicians treating them, be alert to symptoms of influenza-like illness. Treatment with the antiviral drug oseltamivir should be administered as soon as possible after symptom onset. As the benefits of oseltamivir are greatest when administered within 48 hours after symptom onset, clinicians should initiate treatment immediately and not wait for the results of laboratory tests.
WHO has further recommended that, when pandemic vaccines become available, health authorities should consider making pregnant women a priority group for immunization.